Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

Valoctocogene roxaparvovec is an investigational AAV5‐based factor VIII (FVIII) gene therapy that has demonstrated sustained clinical benefit in people with severe haemophilia A.

[1]  T. Buckner,et al.  Evidence of a disability paradox in patient‐reported outcomes in haemophilia , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  K. Pasi,et al.  Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy. , 2020, Blood.

[3]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  G. Pierce.  Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  M. Laffan,et al.  Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. , 2020, The New England journal of medicine.

[6]  L. Tang,et al.  Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries , 2019, Research and practice in thrombosis and haemostasis.

[7]  J. Oldenburg,et al.  Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  A. Iorio,et al.  Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study , 2019, Thrombosis and Haemostasis.

[9]  V. Blanchette,et al.  The Jamaican Haemophilia Registry: Describing the burden of disease , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  D. Perry,et al.  AAV5–Factor VIII Gene Transfer in Severe Hemophilia A , 2017, The New England journal of medicine.

[11]  C. Peterfy,et al.  Effect of late prophylaxis in hemophilia on joint status: a randomized trial , 2017, Journal of thrombosis and haemostasis : JTH.

[12]  P. Camp,et al.  Patient powered prophylaxis: A 12‐month study of individualized prophylaxis in adults with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  C. Terwee,et al.  Health‐related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  R. Kotin,et al.  Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. , 2017, Human gene therapy.

[15]  Carter,et al.  Levels of Human FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice Following Gene Therapy with BMN 270 , 2017 .

[16]  B. Riske,et al.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database. , 2016, Blood.

[17]  V. Blanchette,et al.  Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada , 2016, BMC Hematology.

[18]  K. Wyrwich,et al.  Interpreting important health‐related quality of life change using the Haem‐A‐QoL , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[20]  A. Iorio,et al.  Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[23]  F. Rosendaal,et al.  Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels , 2011, Haemophilia.

[24]  M. Bullinger,et al.  Cross‐cultural development and psychometric evaluation of a patient‐reported health‐related quality of life questionnaire for adults with haemophilia , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.